Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Social Psychology Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Inflammation and Daily Life Study

NCT03771612
View directory record Official record
Conditions
Inflammation
Interventions
Naproxen, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 60 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational

Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients

NCT00805571
View directory record Official record
Conditions
Kidney Transplant Dysfunction
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Not yet recruiting No phase listed Observational

GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial

NCT07551531
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
Insight Molecular Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Neuropeptides and Social Behavior

NCT01680718
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal oxytocin, Intranasal vasopressin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 23, 2026, 3:43 PM EDT
Enrolling by invitation No phase listed Observational

Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

NCT04234139
View directory record Official record
Conditions
Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection, Liver Diseases, Hepatitis, Alcoholic, Alcohol-Induced Disorders
Interventions
liver transplant
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nuevo Amanecer II: Translating a Stress Management Program for Latinas

NCT02931552
View directory record Official record
Conditions
Breast Neoplasms, Psychology, Social
Interventions
Nuevo Amancer-II Stress Management Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Multiple Locations, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Results available

Nuevo Amanecer: Promoting the Psychosocial Health of Latinas

NCT01383174
View directory record Official record
Conditions
Breast Neoplasms, Psychology, Social
Interventions
Peer Support Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Multiple Locations, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

NCT00105235
View directory record Official record
Conditions
Liver Disease, Liver Transplantation
Interventions
Alemtuzumab, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Liver transplant, Immunosuppression withdrawal
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional

Deceased Organ Donor Interventions to Protect Kidney Graft Function

NCT02525510
View directory record Official record
Conditions
Brain Death, Organ Donation, Organ Transplant Failure or Rejection, Delayed Graft Function
Interventions
Pump Eligible - Normothermia - Pump Both Kidneys, Pump Eligible - Hypothermia and Pump Right Kidney, Pump Eligible - Hypothermia and Pump Left Kidney, Not Pump Eligible - Normothermia, Not Pump Eligible - Hypothermia
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

NCT04046549
View directory record Official record
Conditions
Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
Interventions
Belatacept, VIB4920, Thymoglobulin, Methylprednisolone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Results available

AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm

NCT04758637
View directory record Official record
Conditions
Opioid Abuse
Interventions
Overdose Notification
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

NCT00099736
View directory record Official record
Conditions
Kidney Transplantation
Interventions
FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
42
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 23, 2026, 3:43 PM EDT
Active, not recruiting Phase 4 Interventional

Envarsus XR® in Adolescent Renal Transplant Recipients

NCT03266393
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Grafting, Kidney
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Body and Social Behavior

NCT05654441
View directory record Official record
Conditions
Psychology, Social, Inflammation, Defeat, Social, Interaction, Social
Interventions
Influenza vaccine, Placebo
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational

Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients

NCT00225394
View directory record Official record
Conditions
CMV Disease, Viral Resistance, Rejection, Death
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2005 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

NCT00782821
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Rabbit Antithymocyte Globulin, Velcade, Rituxan
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational

Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction

NCT01140152
View directory record Official record
Conditions
Intestinal Transplant, Cellular Rejection
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Mobile-Web Emotion Self-management Tool

NCT02346591
View directory record Official record
Conditions
Stress, Depression
Interventions
Jauntly, Online stress management information
Behavioral
Lead sponsor
Oregon Center for Applied Science, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Phase 2 Interventional

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

NCT07508787
View directory record Official record
Conditions
Renal Transplant Failure and Rejection
Interventions
Siplizumab, Rabbit anti-thymocyte globulin
Drug
Lead sponsor
Nefro Avillion Clinical Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Sacramento, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 3:43 PM EDT